ESSA Pharma Inc. (EPIX)

NASDAQ: EPIX · IEX Real-Time Price · USD
3.60
-0.38 (-9.55%)
At close: Jun 28, 2022 4:00 PM
3.78
+0.18 (5.00%)
After-hours: Jun 28, 2022 5:02 PM EDT
-9.55%
Market Cap 158.61M
Revenue (ttm) n/a
Net Income (ttm) -37.26M
Shares Out 44.06M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 304,281
Open 4.04
Previous Close 3.98
Day's Range 3.57 - 4.04
52-Week Range 3.57 - 30.26
Beta 1.58
Analysts Buy
Price Target 32.03 (+789.7%)
Earnings Date Aug 15, 2022

About EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Can... [Read more...]

Industry Biotechnology
Founded 2009
Employees 25
Stock Exchange NASDAQ
Ticker Symbol EPIX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for EPIX stock is "Buy." The 12-month stock price forecast is 32.03, which is an increase of 789.72% from the latest price.

Price Target
$32.03
(789.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development

EPI-7386 was safe and well-tolerated at all dose levels and schedules tested with plasma target concentrations achieved and clinically important efficacy signals Conference Call and Webcast Today at 5:0...

ESSA Pharma to Present at 2022 Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , June 2, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on develop...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , May 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing ...

ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , April 26, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...

ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal D...

Orally bioavailable ANITAC™ degraders can eliminate full length, mutant and splice variant forms of AR that are expressed in castration-resistant prostate cancer (CRPC) patients ANITAC degraders inhibit...

ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference

South San Francisco, California and Vancouver, Canada, March 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on develo...

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

SOUTH SAN FRANCISCO, California  and VANCOUVER, Canada, March 9, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on develop...

ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at ...

First presentation of preclinical data for ESSA's androgen receptor (AR) N-terminal domain degraders ANIT en bAsed Chimera (ANITAC™) degraders degrade full length, mutant and splice variant forms of AR ...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021

HOUSTON, Texas and VANCOUVER, Canada, Feb. 3, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapie...

ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide ...

HOUSTON and VANCOUVER, BC, Jan. 19, 2022 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the t...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended Septembe...

VANCOUVER, Canada and HOUSTON, Texas, Nov. 18, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapi...

ESSA Pharma to Participate in Three Upcoming Investor Conferences

VANCOUVER, Canada and HOUSTON, Texas, Nov. 8, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapie...

ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat

VANCOUVER , Canada and HOUSTON , Texas, Oct. 28, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel thera...

ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386

-       Data presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics – VANCOUVER, Canada and HOUSTON, Texas, Oct. 7, 2021 /PRNewswire/ - ESSA P...

Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration

IRVING, Texas, and HOUSTON, and VANCOUVER, BC, Oct. 7, 2021 /PRNewswire/ --  Caris Life Sciences®, a molecular science company developing and delivering technologies to revolutionize healthcare, and ESS...

ESSA Pharma to Present at Upcoming September Investor Conferences

VANCOUVER, Canada and HOUSTON, Texas, Aug. 31, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapi...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021

HOUSTON, Texas and VANCOUVER, Canada, Aug. 16, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapie...

ESSA Pharma to Present at the Jefferies Virtual Healthcare Conference

HOUSTON, Texas and VANCOUVER, Canada, May 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021

- Presented promising preliminary pharmacokinetic and clinical data on EPI-7386 in metastatic castration-resistant prostate cancer at 2021 AACR - Raised approximately $150 million in a public offering H...

ESSA Pharma Announces Clinical Collaboration Agreement with Bayer to Evaluate the Combination of EPI-7386 and Darolut...

HOUSTON, Texas and VANCOUVER, Canada, April 28, 2021 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapi...

ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference

HOUSTON, Texas and VANCOUVER, Canada, April 14, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapi...

ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Associati...

HOUSTON, Texas and VANCOUVER, Canada, April 10, 2021 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therap...

ESSA Announces Change to its Board of Directors

HOUSTON, Texas and VANCOUVER, BC, March 26, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies f...

ESSA Pharma Announces Exercise of Option in Connection with Recently Completed $130 Million Financing

VANCOUVER, BC and HOUSTON, March 4, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the ...

ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

HOUSTON and VANCOUVER, BC, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel therap...